Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, Iglesias Rey L, Rubió-Casadevall J, Arrazubi V, Mesía R. Rueda Domínguez A, et al. Among authors: castelo fernandez b. Clin Transl Oncol. 2022 Apr;24(4):670-680. doi: 10.1007/s12094-022-02814-x. Epub 2022 Mar 18. Clin Transl Oncol. 2022. PMID: 35303267 Free PMC article.
Cirrhosis-like radiological pattern in patients with breast cancer.
Gómez Raposo C, Redondo Sánchez A, Guerra-Gutiérrez F, Castelo Fernández B, Gómez Senent S, Espinosa Arranz E, Martínez Martínez B, Zamora Auñón P, González Barón M. Gómez Raposo C, et al. Among authors: castelo fernandez b. Clin Transl Oncol. 2008 Feb;10(2):111-6. doi: 10.1007/s12094-008-0164-2. Clin Transl Oncol. 2008. PMID: 18258510
mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M. Pinto Marín A, et al. Among authors: castelo fernandez b. Urol Oncol. 2012 Jul-Aug;30(4):356-61. doi: 10.1016/j.urolonc.2009.11.008. Epub 2010 Mar 5. Urol Oncol. 2012. PMID: 20207176 Review.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
López González A, Del Barco Berrón S, Grau I, Galan M, Castelo Fernández B, Cortés A, Sánchez Rovira P, Martinez-Bueno A, Gonzalez X, García A, Gener P, Mina L, Alcalá-López D, Sampayo M, Cortés J, Pérez-Garcia JM, Llombart-Cussac A, López-Miranda E. López González A, et al. Among authors: castelo fernandez b. Cancers (Basel). 2022 Nov 29;14(23):5880. doi: 10.3390/cancers14235880. Cancers (Basel). 2022. PMID: 36497361 Free PMC article.